Safinamide: A new add-on drug for the treatment of Parkinson's disease
Journal Title: JOURNAL OF MEDICAL COLLEGE CHANDIGARH - Year 2017, Vol 7, Issue 2
Abstract
Safinamide is a new drug approved for the treatment of Parkinson's disease as an add-on therapy for the patients, who are taking levodopa and carbidopa and are experiencing 'off ' episodes. It has multiple modes of action including reversible inhibition of MAO-B enzyme and modulation of glutamate release. The drug increases the 'on' time and reduces the symptoms of Parkinson's disease without producing troublesome dyskinesia.
Authors and Affiliations
Sangeeta Bhanwra, Rajiv Kumar
Keywords
Related Articles
- EP ID EP312495
- DOI -
- Views 117
- Downloads 0
Septic Pulmonary Embolism Revisited. A Case Report and Points to Ponder
Septic pulmonary embolism is a common but under-diagnosed condition that mimics bacterial pneumonia and tuberculosis. We describe the successful management of a case of septic pulmonary embolism who was misdiagnosed as t...
Lesinurad: A novel drug for the treatment of hyperuricemia associated with Gout in combination with a Xanthine Oxidase Inhibitor
Lesinurad is a selective inhibitor of URAT 1(Uric acid absorption inhibitor) and doesn’t inhibit organic anion transporters (e.g. OAT1 & 3) which make it to be an effective uricosuric agent with minimal clinically signi...
Striae rubra following topical application of Clobetasol propionate
Topical corticosteroids rarely cause serious side effects if they are used as instructed. The risk of side effects increases with increased drug potency, length and frequency of treatment and surface area exposed. Local...
Ethics and research
Not available
Anaesthesiologists' perspective in meningoencehalocele : A case report
Meningoencephalocele is a midline defect of cranial bone fusion which occurs most frequently in the occipital region (75%). The anaesthetic management of this subset of patients in the perioperative period is a formidabl...